about
HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applicationsHDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosisHDL and glucose metabolism: current evidence and therapeutic potentialHigh-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung DiseaseHigh-Density Lipoproteins: Nature's Multifunctional NanoparticlesStructural and Functional Analysis of the ApolipoproteinA-I A164S VariantMendelian randomization in cardiometabolic disease: challenges in evaluating causality.CETP inhibitors and cardiovascular disease: Time to think again.Epigenetic regulation of cholesterol homeostasis.Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus.Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.Structural stability and functional remodeling of high-density lipoproteins.Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.High-Density Lipoprotein - A Hero, a Mirage, or a Witness?Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetesProteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathwayAssociations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism.Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivoSynthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin.Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.Microdomains, Inflammation, and Atherosclerosis.Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study.The Search for Dietary Supplements to Elevate or Activate Circulating Paraoxonases.β3-Adrenoceptor activation upregulates apolipoprotein A-I expression in HepG2 cells, which might further promote cholesterol efflux from macrophage foam cells.Mendelian randomisation applied to drug development in cardiovascular disease: a review.High-density lipoprotein-based drug discovery for treatment of atherosclerosis.Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural InsightsMass spectrometry meets the challenge of understanding the complexity of the lipoproteome: recent findings regarding proteins involved in dyslipidemia and cardiovascular disease.ApoA-I-Directed Therapies for the Management of Atherosclerosis.Niacin as antidyslipidemic drug.Better Indigenous Risk stratification for Cardiac Health study (BIRCH) protocol: rationale and design of a cross-sectional and prospective cohort study to identify novel cardiovascular risk indicators in Aboriginal Australian and Torres Strait IslanTRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis.HDL cholesterol: reappraisal of its clinical relevance.Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease.Lipoproteins and lipoprotein mimetics for imaging and drug delivery.
P2860
Q26779667-2F029EA3-CE8A-492A-819E-B4ABC2B332A2Q26782972-8B80F081-F539-4195-875B-715D4990F9DAQ26996502-216FC25A-1B94-4174-8890-8D767146A7E6Q28075541-03534E79-6B64-4831-88A7-620F0873CEAFQ28077290-09A4E53E-8C52-42D8-AADF-AC961D78BA66Q28551157-8A5CCC4F-8D14-4C3D-A17A-3B0DBC02D309Q30234302-0FBA5AA4-E69D-437A-A011-EF2ECF1252F4Q34109100-4C22FB1D-ECF3-474A-A71A-AC9C978DF925Q34238886-0B283379-3FC2-4FD1-A930-F92933373B6DQ35114943-EB1E5F45-3293-4FD8-B9AE-7B991E794C4CQ35120931-86FBDA51-A7BF-482F-9D30-B55BDD9E43B8Q35428677-243F2F17-3E76-4B46-B304-B846C4843582Q36031087-4E77E771-F321-4DEC-8F75-AA6274FF6A7FQ36141666-BEBF0DFC-8CBE-4B75-9F37-F2DB7CD79D9FQ36197563-66F1F3B5-0A6B-4200-AB21-B947DBAAA306Q36223845-946877F5-E2E8-4447-8356-8F93745F055FQ36344712-39B4C409-225B-4A85-B72E-640E421DD2E3Q36500202-4F9FDA5A-0EA3-4498-B0D4-A99F03465F14Q36503826-3DFD9E30-F3FA-4B6A-B16E-052B72E770D6Q36503844-06AE6B52-CBFC-428D-8CB3-A7CFC152E696Q36548371-B26A9B75-FD98-45F5-8BDF-41E0FE0863DEQ37270341-4E6E776D-938F-4EFA-908E-B4C6AC266CD4Q37446423-3A8FD220-067D-450C-9E7C-D39455E7B0D1Q37556042-5766619F-57A1-485F-A67F-8F3EC3F52857Q37573748-74A8061A-6309-4443-8106-18EF4A7D31EBQ37623996-4D17E70A-F9AD-4C7D-B431-27C72FEE383BQ37624112-6AF6B95F-7D82-47F2-9778-F862936A2454Q37690989-67F35D91-11DB-44C8-BE18-609399B4A2B5Q37691638-CF5541D1-FE4E-47AF-BC3E-3BD93431AED0Q38290764-85E5533A-ED03-4692-8AF2-D550DA90F20EQ38506490-1F3380B3-7BFF-4F87-BC0F-CC43C6F3D815Q38543425-DED75D86-1166-4142-A45A-5D0B08CFD2C6Q38577853-3EA63777-2D8D-484E-99CB-E23EFBD518DAQ38579703-94E25B61-F09D-455E-A429-C8AA024CF58EQ38586930-BF5E72BD-A2A4-4409-BC8C-8D7D4C653B59Q38611359-03EE61F9-7874-485C-BC32-1DEABCA9FDECQ38706492-D3CEC081-3B0B-442F-B3BC-8354DC6D4F3EQ38739884-4EB64E9C-87D4-4E7A-B0BD-FD6C9E50C640Q38807248-B7489B42-FEC4-423B-A61F-C04A302D3692Q38822339-8E6477E6-8AF1-4616-972B-CF4232BF6B40
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HDL-targeted therapies: progress, failures and future.
@en
type
label
HDL-targeted therapies: progress, failures and future.
@en
prefLabel
HDL-targeted therapies: progress, failures and future.
@en
P2093
P356
P1476
HDL-targeted therapies: progress, failures and future.
@en
P2093
Anatol Kontush
Bronwyn A Kingwell
M John Chapman
Norman E Miller
P2888
P304
P356
10.1038/NRD4279
P577
2014-05-23T00:00:00Z